Plains Ventures

Cadenza Bio is a biotechnology company focused on the development of highly selective small-molecule drugs aimed at treating demyelinating and inflammatory diseases. The company is dedicated to creating therapeutic medications that not only alleviate symptoms but also halt disease progression, promote repair, and restore the quality of life for patients. By advancing a new class of Estrogen Receptor targeted small molecules, Cadenza Bio aims to empower patients to regain control over their health and improve their overall well-being.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

PatchRx is a remote therapeutic management platform focused on enhancing medication adherence and patient compliance. It utilizes a comprehensive approach to support clinics in leveraging remote therapeutic monitoring. The platform features a universal smart pill bottle, a patient-facing app, and a web application, all designed to help patients take their medications as prescribed. PatchRx allows users to manage refills and rewards them for maintaining good adherence, while also providing real-time adherence data to healthcare providers. By integrating data-driven technology, PatchRx aims to improve health outcomes and facilitate better communication between patients and their care teams.

Wheeler Bio is a biomanufacturing company established in 2020 in Oklahoma City by Jesse McCool. The company focuses on accelerating the translation of therapeutic innovations into clinical applications through its biomanufacturing platform. By integrating pre-clinical discovery with biomanufacturing, Wheeler Bio aims to fill critical gaps between the discovery phase and early development. Its Portable CMC platform provides biopharma companies with rapid access to quality biomanufacturing, enabling a reliable pathway to clinical trials. This approach is designed to democratize access to comprehensive discovery-to-IND programs, making it easier for clients to navigate the complexities of bringing new therapies to market.

Access Optics is able to combine innovating manufacturing engineering, process development, and optical fabrication with advanced coating technology. The pioneering product development and advanced materials solutions have fostered breakthrough products for leading OEMs in endoscopy, dermatology, aerospace, and chromatography.